Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Journal of Clinical Medicine|July 29, 2023
Bone Mass Changes Following Percutaneous Radiofrequency Ablation, Osteoplasty, Reinforcement, and Internal Fixation of Periacetabular Osteolytic MetastasesWill Jiang, Dennis L Caruana, Christopher M Dussik, et al.
Biomolecules|October 28, 2023
Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma-Proteomic Alteration and Comparison Analysis with the Standard-of-Care ChemoirradiationAndra V Krauze, Yingdong Zhao, Ming-Chung Li, et al.
Surgical Neurology International|December 8, 2021
Cerebellopontine angle ependymoma presenting as isolated hearing loss in an elderly patient: A case report and literature reviewKhaled Dibs, Rahul Neal Prasad, Kajal Madan, et al.
International Journal of Radiation Oncology, Biology, Physics|January 24, 2026
Treatment With Stereotactic Ablative Radiotherapy for patients with Up to 5 Oligometastatic cancer lesions: Long-Term Outcomes of the Nonrandomized Population-Based Phase 2 SABR-5 Clinical TrialCurtis Leclerc, Sarah Baker, Will Jiang, et al.
Frontiers in Oncology|October 24, 2022
The prognostic impact of PD-L1 and CD8 expression in anal cancer patients treated with chemoradiotherapyAngela My Chan, Gloria Roldan Urgoiti, Will Jiang, et al.
International Journal of Radiation Oncology, Biology, Physics|July 15, 2022
Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 TrialSarah Baker, Benjamin Mou, Will Jiang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 23, 2025
Impact of clinical target volume utilization on outcomes in patients with non-spine bone oligometastases treated with stereotactic ablative radiation therapyEmily O'Reilly, Eshawn Johal, Haley Clark, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|September 26, 2025
The Sirt1-Piezo1 Axis Promotes Bone Formation and Repair in MiceDonghao Gan, Yi Ran, Hong Pan, et al.
International Journal of Radiation Oncology, Biology, Physics|June 6, 2022
Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 TrialSarah Baker, Will Jiang, Benjamin Mou, et al.
JAMA Oncology|September 29, 2022
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical TrialRobert Olson, Will Jiang, Mitchell Liu, et al.
Pageof 4